Cofactor Genomics
4044 Clayton Avenue
St. Louis
Missouri
63110
United States
Tel: 314-531-4647
Fax: 314-754-9090
Website: http://www.cofactorgenomics.com/
Email: info@cofactorgenomics.com
About Cofactor Genomics
Cofactor Genomics is leading the charge on moving RNA-seq out of discovery and into diagnostics. Working with the largest life-science and pharmaceutical companies in the world, we’ve developed streamlined and scalable protocols to interrogate RNA. By standardizing RNA-seq products, and developing validated clinical assays, we’re trusted partners in advancing precision medicine. Alongside our internal novel biomarker development efforts, Cofactor offers pre-clinical RNA-seq, clinical RNA-seq, and CDx partnerships.
15 articles about Cofactor Genomics
-
Stanford University Joins Cofactor Genomics’ Clinical Trial Evaluating Immunotherapy Predictive Diagnostic Assay Across 11 Cancers
7/11/2023
Stanford University and Cofactor Genomics, the company bridging the precision medicine gap, announced that Stanford will join Cofactor’s PREDAPT clinical trial evaluating use of the company’s OncoPrism™ predictive diagnostic assay across 11 cancers.
-
Culmination Bio and Cofactor Genomics Leverage Largest Biobank in the U.S. for PREDAPT Precision Medicine Clinical Trial
5/9/2023
Culmination Bio today announced a partnership to leverage samples and data from one of the largest biobanks in the country to fuel the development of Cofactor Genomic’s OncoPrism™ test in 11 cancers.
-
Cofactor Genomics Opens Enrollment for Non-small Cell Lung Cancer Study of OncoPrism Predictive Diagnostic Assay
12/14/2022
Cofactor Genomics, the diagnostics company bridging the precision medicine gap, today announced commencement of a study of its OncoPrism™ assay in non-small cell lung cancer (NSCLC), the second indication being studied in the company’s national PREDAPT study that will ultimately encompass 11 cancers.
-
Cofactor Genomics Opens Early Access to New T Cell Exhaustion Models through Predictive Immune Modeling Platform
11/6/2019
Announces “Functional to FFPE” Early-Access Grant Program
-
Cofactor Joins FNIH Biomarkers Consortium to Add Predictive Immune Modeling Expertise as New Resource for Multidimensional Biomarker Discovery
6/4/2019
Contributing to both the Cancer and Inflammation and Immunity Steering Committees
-
Cofactor Genomics Opens $100,000 Predictive Immune Modeling Grant Program for Biomarker Discovery
2/6/2019
Awards Scientists and Clinicians Who Create Predictive Immune Models and Multidimensional Biomarkers Using the Cofactor ImmunoPrismTM Assay
-
Cofactor Genomics to Provide Solid Tumor Immune Profiling for Genocea Biosciences
12/4/2018
-- Pilot study to evaluate use of Cofactor assay in Genocea’s neoantigen vaccine clinical trial --
-
Cofactor Genomics Launches ImmunoPrismTM Immune Profiling Kit, for Use in Clinical Sequencing Laboratories
10/30/2018
Cofactor Genomics, a clinical RNA sequencing and translational assay developer, announced today the launch of a RNA-based immune profiling kit developed for laboratories wishing to derive the immune composition of tumor samples
-
Cofactor Genomics to Present Immune Profiling Results of Sarcoma Study with the Fred Hutchinson Cancer Research Center
1/9/2018
Cofactor Genomics announced today that results from a collaborative study with the Fred Hutchinson Cancer Research Center will be presented at the Molecular Medicine Tri-Conference in February.
-
Cofactor Genomics Announces $18 Million Funding In An Oversubscribed Series-A Round To Bring RNA To Precision Medicine
9/19/2017
-
Cofactor Genomics Launches Pinnacle: A CAP-CLIA Certified RNA-Based Oncology Assay
2/16/2017
-
Cofactor Genomics Partners With FLX Bio For Immuno-Oncology Analysis Platform
12/1/2016
-
Cofactor Genomics Acquires San Francisco Based Narus Biotech
2/4/2016
-
Cofactor Genomics Awarded $1.5 Million NIH Grant For Further Development Of Circular RNA Enrichment Technology
7/22/2015
-
SAGE Labs, Inc. Launches RNA-Sequencing Services in Partnership With Cofactor Genomics
10/8/2013